Amdocs Limited Stock Return On Equity
AOS Stock | EUR 75.84 0.46 0.60% |
Fundamental analysis of Amdocs allows traders to better anticipate movements in Amdocs' stock price by examining its financial health and performance throughout various phases of its business cycle.
Amdocs |
Amdocs Limited Company Return On Equity Analysis
Amdocs' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Amdocs Return On Equity | 0.15 |
Most of Amdocs' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Amdocs Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition |
Based on the latest financial disclosure, Amdocs Limited has a Return On Equity of 0.1523. This is 101.27% lower than that of the Technology sector and 100.8% lower than that of the Software - Infrastructure industry. The return on equity for all Germany stocks is 149.13% lower than that of the firm.
Did you try this?
Run ETFs Now
ETFsFind actively traded Exchange Traded Funds (ETF) from around the world |
All Next | Launch Module |
Amdocs Fundamentals
Return On Equity | 0.15 | |||
Return On Asset | 0.0652 | |||
Profit Margin | 0.12 % | |||
Operating Margin | 0.15 % | |||
Current Valuation | 10.29 B | |||
Shares Outstanding | 120.59 M | |||
Shares Owned By Insiders | 0.01 % | |||
Shares Owned By Institutions | 98.75 % | |||
Price To Earning | 22.06 X | |||
Price To Book | 2.98 X | |||
Price To Sales | 2.22 X | |||
Revenue | 4.58 B | |||
Gross Profit | 1.62 B | |||
EBITDA | 899.33 M | |||
Net Income | 549.5 M | |||
Cash And Equivalents | 449.7 M | |||
Cash Per Share | 3.28 X | |||
Total Debt | 645.12 M | |||
Debt To Equity | 3.30 % | |||
Current Ratio | 1.35 X | |||
Book Value Per Share | 29.42 X | |||
Cash Flow From Operations | 756.72 M | |||
Earnings Per Share | 4.18 X | |||
Price To Earnings To Growth | 1.14 X | |||
Target Price | 87.75 | |||
Number Of Employees | 31 K | |||
Beta | 0.66 | |||
Market Capitalization | 10.24 B | |||
Total Asset | 6.39 B | |||
Z Score | 9.0 | |||
Annual Yield | 0.02 % | |||
Five Year Return | 1.35 % | |||
Net Asset | 6.39 B | |||
Last Dividend Paid | 1.58 |
About Amdocs Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Amdocs Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Amdocs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Amdocs Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Amdocs Stock
Amdocs financial ratios help investors to determine whether Amdocs Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Amdocs with respect to the benefits of owning Amdocs security.